ArticleFrontiers in bioengineering and biotechnology2026
MXene-based functionalized platforms for high-performance MALDI-TOF MS: application in early-stage bloodstream infection biomarker screening.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study developed a MALDI-TOF MS metabolomics analysis method based on MXene nanomaterial functionalization platform for early diagnosis of bloodstream infections (BSI). Currently, BSI detection mainly relies on methods such as blood culture, PCR, and single biomarkers (such as PCT, CRP), which have problems such as long detection time, low sensitivity, and insufficient specificity. Therefore, it is urgent to establish a high-throughput detection technology that is fast, sensitive, and capable of multidimensional analysis. Method: This study synthesized and characterized MXene nanomaterials, and utilized their ultra-high specific surface area and controllable surface functional groups to construct MXene matrices, significantly improving the enrichment and ionization efficiency of serum metabolites. We used this platform to perform metabolic profiling analysis on 50 BSI positive samples and 50 non BSI control samples, and analyzed the data using principal component analysis (PCA), orthogonal partial least squares discriminant analysis (OPLS-DA), and heatmaps. Result: The platform achieved an area under the curve (AUC) of 0.981, a sensitivity of 92%, and a specificity of 96% in BSI diagnosis, demonstrating superior performance compared to traditional single biomarkers. Further screening identified multiple potential metabolic markers (M/Z=203.64, 206.75, 218.67, 220.70), all of which had AUCs higher than 0.969. Discussion: This study not only confirmed the application potential of MXene in mass spectrometry, but also provided a highly sensitive and high-throughput metabonomics technology platform for early screening of infectious diseases. This progress is expected to promote the transformation of BSI diagnosis from single indicator detection to multidimensional metabolic fingerprint analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.